Step 1 topics → Hematology and Oncology → Hemolytic Uremic Syndrome (HUS)

Hemolytic Uremic Syndrome (HUS)

USMLE Step 1 trap: Confuses Shiga toxin-mediated endothelial injury in HUS with direct bacterial invasion of the kidney. HUS is caused by Shiga toxin (from E. coli O157:H7 or Shigella) that is absorbed systemically and directly damages glomerular endothelial cells, triggering thrombotic microangiopathy.

Hemolytic Uremic Syndrome (HUS) is a thrombotic microangiopathy defined by the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury on USMLE Step 1. The classic form is triggered by Shiga toxin-producing E. coli O157:H7 (STEC), most commonly following bloody diarrhea — and the most dangerous wrong answer here is giving antibiotics. Antibiotic-induced bacterial lysis floods the gut with preformed Shiga toxin, dramatically increasing systemic absorption and worsening HUS risk. The toxin is absorbed systemically, homes to glomerular endothelial cells, and initiates platelet-fibrin thrombus formation in the microvasculature. You need to understand not just the triad but the mechanistic path from contaminated food to renal failure.

The exam tests HUS from multiple angles: pure recall of the triad, application of the mechanism to explain clinical findings, and scenario-based questions where you must pick the right management move (including recognizing what NOT to do). A classic trap is a vignette of a child with bloody diarrhea and early renal dysfunction where one answer choice offers antibiotics — that's the kill shot if you don't know why antibiotics are contraindicated. The exam also increasingly tests atypical HUS as a separate entity with a completely different pathophysiology and treatment.

The biggest confusion zone is conflating HUS with TTP. Both are thrombotic microangiopathies and share MAHA and thrombocytopenia, but they differ in their dominant organ involvement and underlying mechanism. HUS hits the kidney hard; TTP hits the brain. TTP is driven by ADAMTS13 deficiency; HUS is driven by Shiga toxin or complement dysregulation. USMLE Step 1 will expect you to know which features distinguish them and to recognize atypical HUS as a complement-mediated disorder — not just a toxin variant.

From real student decks
70%have cards covering this topic
51%have mature cards

Common misconceptions

Common mistake
Wrong: HUS is caused by direct bacterial invasion of the renal endothelium by E. coli.
Right: HUS is caused by Shiga toxin (from E. coli O157:H7 or Shigella) that is absorbed systemically and directly damages glomerular endothelial cells, triggering thrombotic microangiopathy.
E. coli O157:H7 does not invade the kidney directly — it colonizes the gut and produces Shiga toxin there. The toxin is then absorbed into the bloodstream and travels systemically to the glomerular endothelium, where it binds Gb3 receptors and triggers endothelial cell death. This leads to platelet aggregation and fibrin deposition in the microvasculature — the defining mechanism of thrombotic microangiopathy in HUS.
Common mistake
Wrong: Antibiotics should be given for E. coli O157:H7 diarrhea to prevent HUS.
Right: Antibiotics are contraindicated in E. coli O157:H7 infection because bacterial lysis releases more Shiga toxin, increasing the risk of HUS.
Giving antibiotics to a patient with E. coli O157:H7 infection seems intuitive but is actually harmful. Antibiotic-induced bacterial lysis causes a massive dump of preformed Shiga toxin into the gut lumen, dramatically increasing systemic absorption. Multiple studies have shown this raises the risk of progression to HUS — so the correct management is supportive care (IV fluids, electrolyte monitoring, dialysis if needed), with no antibiotics.
Common mistake
Gap: Missing atypical HUS as a complement-mediated disorder treated with eculizumab, distinct from Shiga toxin HUS
Atypical HUS is caused by complement dysregulation (factor H or I mutations) rather than Shiga toxin, and is treated with eculizumab (anti-C5 antibody) rather than supportive care.
Atypical HUS has nothing to do with Shiga toxin. It results from loss-of-function mutations in complement regulatory proteins like factor H or factor I, causing uncontrolled alternative complement pathway activation that damages endothelial cells. Because the driver is complement dysregulation rather than a toxin, supportive care alone is insufficient — eculizumab, a monoclonal antibody that blocks C5 cleavage and terminal complement activation, is the targeted treatment.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the mechanism of classic HUS: Shiga toxin is produced by E. coli O157:H7 or Shigella, absorbed from the gut, and directly damages glomerular endothelial cells — this triggers thrombotic microangiopathy, NOT direct bacterial invasion of the kidney.
  2. Identify the HUS triad (microangiopathic hemolytic anemia, thrombocytopenia, acute kidney injury) and know that renal involvement is what distinguishes HUS from TTP, which predominantly causes neurological symptoms.
  3. Recognize that antibiotics are contraindicated in E. coli O157:H7 infection because bacterial lysis increases Shiga toxin release, worsening HUS risk — supportive care (fluids, dialysis if needed) is the correct approach for classic HUS.
  4. Distinguish atypical HUS as a complement-mediated disorder caused by mutations in complement regulatory proteins (e.g., factor H or factor I), treated with eculizumab (anti-C5 monoclonal antibody), not supportive care alone.

Can you avoid these mistakes?

A 6-year-old presents with 4 days of bloody diarrhea, now developing oliguria and pallor. Labs show anemia with schistocytes, platelet count of 45,000, and creatinine of 3.2. What is the diagnosis, what organism is responsible, and what is the single most important medication to AVOID?
How does Shiga toxin cause acute kidney injury? Walk through the mechanism from toxin absorption to glomerular damage — do not just name the triad.
A patient with recurrent HUS has no recent diarrheal illness and no identifiable infection. Genetic testing reveals a factor H mutation. How does this differ mechanistically from classic HUS, and what is the appropriate treatment?
A vignette describes a child with MAHA, thrombocytopenia, and confusion but minimal renal dysfunction. Another describes a child with MAHA, thrombocytopenia, and acute kidney injury after bloody diarrhea. Which is HUS and which is TTP — and what single lab (if applicable) or clinical feature clinches the distinction?

Related topics

Platelet Physiology and Primary Hemostasis Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function

See how your Anki deck covers this topic.

Upload your deck for a free audit →